EU panel backs approval of GSK's cancer drugs Tafinlar and Tyverb

07/2/2013 | Pharmaceutical Business Review Online

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of GlaxoSmithKline's Tafinlar, or dabrafenib, as a treatment for unresectable or metastatic melanoma in patients with the BRAF V600 mutation. GSK's Tyverb, or lapatinib, along with trastuzumab, was also recommended for approval as combination therapy for certain breast cancer patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC